Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

doi:10.1016/S0140-6736(15)61412-X

The Lancet

Volume 386, Issue 10003, 17–23 October 2015, Pages 1546-1555

https://doi.org/10.1016/S0140-6736(15)61412-X Get rights and content

Summary

Background

The quantification of the burden of disease attributable to hepatitis B virus (HBV) infection and the adaptation of prevention and control measures requires knowledge on its prevalence in the general population. For most countries such data are not routinely available. We estimated the national, regional, and global prevalence of chronic HBV infection.

Methods

For this systematic review and pooled analysis, we searched for data on prevalence of chronic HBV infection published between Jan 1, 1965, and Oct 23, 2013, in the databases Medline, Embase, CAB Abstracts (Global health), Popline, and Web of Science. We included studies reporting the hepatitis B surface antigen (HBsAg) serological marker of chronic HBV infection in non-high-risk groups and extracted data into a customised database. For each country, we calculated HBsAg prevalence estimates and 95% CIs weighted by study size. We extrapolated prevalence estimates to population sizes in 2010 to obtain the number of individuals with chronic HBV infection.

Findings

Of the 17 029 records screened, 1800 report on the prevalence of HBsAg covering 161 countries were included. HBsAg seroprevalence was 3·61% (95% CI 3·61–3·61) worldwide with highest endemicity in countries of the African region (total 8·83%, 8·82–8·83) and Western Pacific region (total 5·26%, 5·26–5·26). Within WHO regions, prevalence ranged from 0·20% (0·19–0·21; Mexico) to 13·55% (9·00–19·89; Haiti) in the Americas, to 0·48% (0·12–1·90; the Seychelles) to 22·38% (20·10–24·83; South Sudan) in the African region. We estimated that in 2010, globally, about 248 million individuals were HBsAg positive.

Interpretation

This first global assessment of country-level population prevalence of chronic HBV infection found a wide variation between countries and highlights the need for continued prevention and control strategies and the collection of reliable epidemiologic data using standardised methodology.

Funding

World Health Organization.

Introduction

Chronic hepatitis B virus (HBV) infection continues to be a major public health issue worldwide1, 2, 3, 4 despite the availability of an effective vaccine and potent antiviral treatments. The risk of developing chronic HBV infection decreases with age at infection, from about 90% when infected perinatally up to 6 months of age to 20–60% between the ages of 6 months and 5 years.1, 5 25% of people who acquire HBV as children will develop primary liver cancer or cirrhosis as adults.⁶ Recent Global Burden of Disease estimates indicate a high morbidity and mortality attributable to chronic HBV, despite decreases over the past decades.7, 8

In sub-Saharan Africa and east Asia, transmission predominantly occurs in infants and children by perinatal and horizontal routes (ie, resulting from close contact which is not parenteral, perinatal, or sexual in nature) whereas in more industrialised countries, rates of new infection and acute disease are highest among young adults and transmission predominantly occurs via injection drug use and high-risk sexual behaviours.9, 10, 11, 12, 13

In 2014, the 67th World Health Assembly of the WHO reaffirmed the resolution on viral hepatitis prevention and control highlighting the need to monitor viral hepatitis prevention, diagnosis and treatment progress.¹⁴ Accurate, national-level epidemiological information is imperative to inform prevention and control priorities, to assess the impact of implemented strategies and for updating burden of disease estimates. However, there are no up-to-date global systematic reviews reporting country-level chronic HBV prevalence. Previous systematic reviews on HBV prevalence were limited in scope (eg, they focused on specific regions or populations).15, 16, 17, 18, 19, 20

We report national-level prevalence estimates of chronic HBV derived by a systematic review of peer-reviewed literature reporting HBV prevalence (hepatitis B surface antigen [HBsAg]) in the general population for all countries for which sero-epidemiologic data were available. We also estimate the number of people living with chronic HBV infection on a national, regional, and global level and address changes over time.

Section snippets

Search strategy and study selection

We undertook and report our systematic review in line with the criteria outlined in the PRISMA guidelines.²¹ We did a systematic search on articles published between Jan 1, 1965, and Oct 23, 2013, in the databases Medline, Embase, CAB Abstracts (Global health), Popline, and Web of Science. We developed a search strategy and adapted it for each database using a combination of Medical Subject Headings (MeSH) and free text including terms related to HBV and to prevalence (appendix). We

Results

After removal of duplicates and initial screening, we reviewed 4310 papers in full, of which 1800 eligible reports on the prevalence of HBsAg covering 161 countries were included in the systematic review (figure 1). Included studies on HBsAg entailed 109 415 627 individuals. The highest numbers of reports were available for China (n=167), India (n=129), Brazil (n=108), and Nigeria (n=85).

On a global level, HBsAg prevalence was 3·61% (95% CI 3·61–3·61). HBsAg seroprevalence and the number of

Discussion

This global systematic review showed that in 2010, about 248 million individuals in the general population, worldwide were chronically infected with HBV. We noted a wide variation in the estimates of HBsAg prevalence between countries, which might be partly explained by varying risk factors and transmission routes across countries. Prevalence estimates at the country level indicate a high burden of infection in sub-Saharan Africa and some countries in the Western Pacific region in particular.

References (33)

RP Beasley
Rocks along the road to the control of HBV and HCC
Ann Epidemiol
(2009)
R Beasley et al.
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan
Lancet
(1981)
JJ Ott et al.
Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity
Vaccine
(2012)
PK Nelson et al.
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
Lancet
(2011)
JI Esteban et al.
The changing epidemiology of hepatitis C virus infection in Europe
J Hepatol
(2008)
The ABCs of Hepatitis
WJ Edmunds et al.
The influence of age on the development of the hepatitis B carrier state
Proc R Soc Lond B
(1993)
Update: recommendations to prevent hepatitis B virus transmission-United States
MMWR
(1995)
D Lavanchy
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
J Viral Hepat
(2004)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
Lancet
(2015)

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Lancet

(2015)

WJ Edmunds et al.

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas

Epidemiol Infect

(1996)

CF Kiire

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa

Gut

(1996)

EE Mast et al.

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on immunization practices (ACIP) Part II: immunization of adults

MMWR

(2006)

J Zhang et al.

Epidemiology of hepatitis B in Canada

Can J Infect Dis

(2001)

Hepatitis B. Global alert and response

(2002)

Cited by (2124)

CCL20 and CD8A as potential diagnostic biomarkers for HBV-induced liver fibrosis in chronic hepatitis B
2024, Heliyon
The main cause of the liver fibrosis (LF) remains hepatitis B virus (HBV) infection, especially in China. Histologically, liver fibrosis still occurs progressively in chronic hepatitis B (CHB) patients, even if HBV-DNA is negative or undetectable. The diagnosis of LF is beneficial to control the development of it, also it may promote the reversal of LF. Although liver biopsy is the gold standard of diagnosis in LF at present, it isa traumatic diagnosis. There are no diagnostic biomarkers as yet for the condition. It is badly in need of biomarkers clinically, which is simple to test, minimally invasive, highly specific, and sensitive. Early detection of HBV-LF development is crucial in the prevention, treatment, and prognosis prediction of HBV-LF. Cytokines are closely associated with both immune regulation and inflammation in the progression of hepatitis B virus associated-liver fibrosis (HBV-LF). In this bioinformatic study, we not only analyzed the relationship between HBV-LF and immune infiltration, but also identified key genes to uncover new therapeutic targets.
To find potential biomarkers for liver fibrosis in the development of chronic hepatic B patients.
We obtained two sets of data including CHB/healthy control and CHB/HBV-LF from the Integrated Gene Expression (GEO) database to select for differential expression analysis. Protein-protein interaction (PPI) network was also generated, while key genes and important gene modules involved in the occurrence and development of HBV-LF were identified. These key genes were analyzed by functional enrichment analysis, module analysis, and survival analysis. Furthermore, the relationship between these two diseases and immune infiltration was explored.
Among the identified genes, 150 were individually associated with CHB and healthy control in the differential gene expression (DGE) analysis. While 14 with CHB and HBV-LF. It was also analyzed in the Robust rank aggregation (RRA) analysis, 34 differential genes were further identified by Cytohubba. Among 34 differential genes, two core genes were determined: CCL20 and CD8A. CCL20 was able to predict CHB positivity (area under the receiver operating characteristic curve [AUC-ROC] = 0.883, 95% confidence interval [CI] 0.786–0.963), while HBV-LF positivity ([AUC-ROC] = 0.687, 95% confidence interval [CI] 0.592–0.779). And CD8A was able to predict CHB positivity ([AUC-ROC] = 0.960, 95% confidence interval [CI] 0.915–0.992), while HBV-LF positivity ([AUC-ROC] = 0.773, 95% confidence interval [CI] 0.680–0.856). Relationship between CCL20 gene expression and LF grades was P < 0.05, as well as CD8A.
CCL20 and CD8A were found to be potential biomarkers and therapeutic targets for HBV-LF. It is instructive for research on the progression of LF in HBV patients, suppression of chronic inflammation, and development of molecularly targeted-therapy for HBV-LF.
A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD
2024, Kidney International Reports
Hepatitis B virus (HBV) vaccination is crucial for seronegative patients with advanced chronic kidney disease (CKD) for protection during dialysis while preparing for transplantation. A standard regimen for HBV vaccination requires 24 weeks to be completed. An accelerated HBV vaccination regimen completed within 8 weeks has shown early effective seroconversion in healthcare workers. However, data for patients with advanced CKD are limited.
A randomized controlled trial was conducted in patients with advanced CKD (estimated glomerular filtration rate [GFR] <30 ml/min per 1.73 m²) and patients on dialysis. The patients were randomly assigned to either a standard HBV vaccination regimen (Engerix B; 40 μg at 0, 4, 8, and 24 weeks) or an accelerated regimen (40 μg at 0, 1, 4, and 8 weeks). The hepatitis B surface antibodies (anti-HBs) were measured at 12, 28, and 52 weeks. Seroconversion were defined as anti-HBs ≥10 IU/l.
At 12 weeks, among the intention-to-treat (ITT) population of 133 participants (65 in the accelerated and 68 in the standard groups), the accelerated group demonstrated significantly higher rates of seroconversion (83.08% vs. 63.24%, P = 0.01). In the per-protocol (PP) analysis of 125 patients (62 in the standard and 63 in the accelerated groups), the accelerated group exhibited higher seroconversion rate compared with the standard group (85.71% vs. 69.35%, P = 0.03). At 28 and 52 weeks, the seroconversion rates were similar between the 2 groups.
In patients with advanced CKD, the accelerated HBV vaccination regimen demonstrated a significantly higher seroconversion rate at 12 weeks of vaccination. This finding suggests that the accelerated regimen is an effective option to achieve rapid seroconversion before initiating hemodialysis or before undergoing kidney transplantation.
Performance evaluation of the Access HBsAg and Access HBsAg confirmatory assays on the DxI 9000 Access Immunoassay Analyzer
2024, Practical Laboratory Medicine
This study evaluated the clinical and analytical performances of the Access HBsAg and the Access HBsAg Confirmatory assays on the DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
Diagnostic specificity and sensitivity of the Access HBsAg and Access HBsAg Confirmatory assays were evaluated by comparing the Access assays to the final HBsAg sample status determined using the Architect, PRISM, or Elecsys HBsAg assays, along with Architect or PRISM HBsAg Confirmatory assays. Imprecision, sensitivity on seroconversion panels, analytical sensitivity on WHO, and recognition of HBV variants were also evaluated.
A total of 7534 samples were included in the analysis (6047 blood donors, 1032 hospitalized patients, 455 positive patients’ samples). Access HBsAg assay sensitivity and specificity were at 100.00% (99.19–100.0) and 99.92% (99.82–99.97), respectively. Sensitivity of Access HBsAg Confirmatory assay was 100.00% (99.21–100.0) on the 464 HBsAg positive samples. The use of a high positive algorithm for the Access HBsAg assay, wherein samples with S/CO ≥ 100.00 were considered positive without requiring repeat or confirmatory testing, was successfully evaluated with all 450 specimens with S/CO greater than 100.00 (sensitivity 100.00%; 99.19–100.0). Access HBsAg assay demonstrated good analytical performance, equivalent recognition of seroconversion panels compared to Architect assay, and an analytical sensitivity between 0.022 and 0.025 IU/mL. All HBV genotypes, subtypes and mutants were well detected without analytical sensitivity loss.
Access HBsAg and Access HBsAg Confirmatory assays demonstrated robust performances. They provide low samples volume requirements and a simplified process, no systematic retesting for high positive samples.
Porto-sinusoidal vascular disorder in chronic HBV: A significant coexistence not to be overlooked
2024, JHEP Reports
Porto-sinusoidal vascular disorder (PSVD) encompasses a group of liver diseases with vascular abnormalities that can cause portal hypertension in the absence of cirrhosis. The new diagnostic criteria allow for coexistence with other liver diseases, however its relationship with chronic hepatitis B (CHB) remains unclear. This study aimed to assess HBV prevalence in a PSVD cohort and evaluate its clinical impact.
This retrospective study was conducted on patients with PSVD at Hospital Clínic Barcelona. HBV serology was evaluated, and patients were categorized into HBV chronic infection, past infection, or no HBV exposure. Clinical characteristics and outcomes were compared.
We included 155 patients with PSVD. Prevalence of CHB and past HBV infection in patients with PSVD was higher than in the general population (5.8% vs. 0.5%, p <0.0001 and 20% vs. 9.1%, p <0.0001, respectively). Patients with CHB had a significant delay in PSVD diagnosis compared to those without CHB (11 [5–25] vs. 1 [0–3] years, p = 0.002) and had a more advanced disease (MELD score 12 [9–17] vs. 9 [7–11], p = 0.012) at the time of PSVD diagnosis. The clinical evolution of PSVD in patients with CHB was marked by a significantly higher transplantation rate at the last follow-up (33% vs. 4.1%, p = 0.001).
Recognizing the coexistence of PSVD and CHB is important for timely diagnosis and optimal management, highlighting the potential benefits of specialized care for potentially improved outcomes.
The new diagnostic criteria for porto-sinusoidal vascular disorder (PSVD) allow for coexistence with other liver diseases. The results of the present study highlight, for the first time, a non-negligible prevalence of chronic hepatitis B in the PSVD population that was previously unknown. Coexistence may challenge and delay the PSVD diagnosis and is associated with a more unfavorable clinical course. Our findings will increase awareness of this coexistence and improve PSVD diagnosis and management. Furthermore, the data will encourage new studies to determine the prevalence and clinical behavior of other chronic liver diseases that coexist with PSVD.
Hepatitis B virus infection, associated factors, knowledge and vaccination status among household contacts of hepatitis B index cases in Mwanza, Tanzania
2024, IJID Regions
To determine the prevalence of hepatitis B virus (HBV) infection, knowledge regarding HBV, vaccination status, and associated factors among household contacts of HBV index cases in Mwanza, Tanzania.
Between July and August 2023, a cross-sectional study involving 97 index cases and 402 household contacts was conducted. Data were collected using pre-tested structured questionnaire and blood samples were collected from household contacts for HBV surface antigen (HBsAg) testing.
The prevalence of HBV among household contacts was 5.4% (95% confidence interval, 2.9-9.0) with a significantly high proportion observed in > 45 years (16.6%) and in males (9.9%). A total of 40.0% of the household contacts had completed the full HBV vaccination series. On multivariate analysis, being male was significantly associated with HBsAg positivity (odds ratio: 7.16, 95% confidence interval: 1.81-28.2, P = 0.005).
About one-tenth of adults’ male household contacts were HBsAg positive. In addition, the majority of household contacts had poor to fair knowledge regarding HBV infection with more than half being unvaccinated against HBV. There is a need to enhance awareness and education regarding HBV infection among household contacts in Tanzania and other low- and middle-income countries.
Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease
2024, Journal of Ethnopharmacology
Chronic liver diseases mainly include chronic viral liver disease, metabolic liver disease, cholestatic liver disease (CLD), autoimmune liver disease, and liver fibrosis or cirrhosis. Notably, the compound formulas of traditional Chinese medicine (TCM) is effective for chronic liver diseases in clinical trials and basic research in vivo, which provide evidence of chronic liver disease treatment with integrated TCM and traditional Western medicine.
This paper aims to provide a comprehensive review of the compound formulas of TCM for treating different chronic liver diseases to elucidate the composition, main curative effects, and mechanisms of these formulas and research methods.
Different keywords related to chronic liver diseases and keywords related to the compound formulas of TCM were used to search the literature. PubMed, Scopus, Web of Science, and CNKI were searched to screen out original articles about the compound formulas of TCM related to the treatment of chronic liver diseases, mainly including clinical trials and basic in vivo research related to Chinese patent drugs, classic prescriptions, proven prescriptions, and hospital preparations. We excluded review articles, meta-analysis articles, in vitro experiments, articles about TCM monomers, articles about single-medicine extracts, and articles with incomplete or uncertain description of prescription composition. Plant names were checked with MPNS (http://mpns.kew.org).
In this review, the clinical efficacy and mechanism of compound formulas of TCM were summarized for the treatment of chronic viral hepatitis, nonalcoholic fatty liver disease, CLD, and liver fibrosis or cirrhosis developed from these diseases and other chronic liver diseases. For each clinical trial and basic research in vivo, this review provides a detailed record of the specific composition of the compound formulas of TCM, type of clinical research, modeling method of animal experiments, grouping methods, medication administration, main efficacy, and mechanisms.
The general development process of chronic liver disease can be summarized as chronic hepatitis, liver fibrosis or cirrhosis, and hepatocellular carcinoma. The compound formulas of TCM have some applications in these stages of chronic liver diseases. Owing to the continuous progress of medical technology, the benefits of the compound formulas of TCM in the treatment of chronic liver diseases are constantly changing and developing.

View all citing articles on Scopus

View full text

ArticlesEstimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Summary

Background

Methods

Findings

Interpretation

Funding

Introduction

Section snippets

Search strategy and study selection

Results

Discussion

Ann Epidemiol

Lancet

Vaccine

Lancet

J Hepatol

The ABCs of Hepatitis

The influence of age on the development of the hepatitis B carrier state

Proc R Soc Lond B

Update: recommendations to prevent hepatitis B virus transmission-United States

MMWR

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

J Viral Hepat

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Lancet

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

Lancet

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas

Epidemiol Infect

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa

Gut

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on immunization practices (ACIP) Part II: immunization of adults

MMWR

Epidemiology of hepatitis B in Canada

Can J Infect Dis

Hepatitis B. Global alert and response

Articles
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013